Reason to trust
How Our News is Made
Strict editorial policy that focuses on accuracy, relevance, and impartiality
Ad discliamer
Morbi pretium leo et nisl aliquam mollis. Quisque arcu lorem, ultricies quis pellentesque nec, ullamcorper eu odio.
There is a lot of excitement and optimism surrounding the potential approval of the first spot Bitcoin ETF in the US. With the chances of approval growing stronger by the day, the SEC may likely approve the first spot BTC ETF before the end of 2023 or early next year. Meanwhile, according to market experts, the price of Bitcoin may reach $100,000 upon approval. This positions BTC as the best crypto to invest in. However, Injective (INJ) and InQubeta (QUBE) could outperform BTC in growth and profit, making them altcoins to watch.
In this post, we will cover the potential of Injective and InQubeta. We will also explore the price outlook of Bitcoin if an ETF is approved.
InQubeta (QUBE): Outperforming Bitcoin
While InQubeta (QUBE) isn’t as established as either Bitcoin or Injective, it has incredible potential. It is among the emerging projects on the initial coin offering list and appears to be dominating in this space. It is in the fifth round of its presale and has raised a whopping $4.6 million at the time of writing. This is a testament to its unique offering and growth potential. According to experts, its value will rise by 3,000% after launch, positioning it as one of the new DeFi projects to anticipate.
So, what is InQubeta? This blockchain-based project aims to reimagine the fundraising landscape of the AI industry by introducing a new approach. It will become the world’s first crowdfunding platform to allow AI startups to raise funds through cryptocurrency, which will be its utility token, QUBE. Also, it seeks to make the AI market accessible to all, thereby providing an opportunity to enjoy the profits that come with investing early in cutting-edge AI innovations. You can become an early adopter of this project by following the link below.
Bitcoin (BTC): Road to $100,000
The bull season is on the horizon but there have been disagreements regarding the developments that will usher it in. A faction believes that the approval of the first spot Bitcoin ETF will bring in institutional investors and billions of dollars into the market, which will see its value skyrocket. On the other hand, another group believes that the Bitcoin halving will play the most crucial role.
Despite this, both parties believe Bitcoin is set for a bullish course. According to analysts, BTC may reach the $100,000 mark if its ETF is approved. With the filings being assessed by the SEC at the moment, they could potentially be approved in November or early next year. Meanwhile, Bitcoin has been reacting positively to this development as it trades above $35,000. Does this make BTC the best cryptocurrency to buy now? Very likely.
Injective (INJ): A Top Altcoin
What is Injective (INJ)? It is a blockchain built for finance. Injective powers next-generation decentralized finance (DeFi) applications, including decentralized and derivatives exchanges, lending protocols, and prediction markets. The decentralized cross-chain bridging infrastructure is compatible with Ethereum, non-EVM chains like Solana, and IBC-enabled blockchains.
The above makes Injective a key player in the crypto landscape and ranks among the top altcoins. It has been gaining traction and market momentum and appears poised for a more significant bullish run. Hence, Injective is an investment not to miss out on.
Conclusion
Bitcoin has been tipped to reach $100,000 if the first spot ETF is approved by the SEC. However, for more significant ROIs, tokens to consider are Injective and InQubeta. These cryptocurrencies have lower market caps than BTC, leaving them with more room for growth. Therefore, they are more promising investment opportunities.
